Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears 
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Apple Turns 50: From Garage Startup to AI Crossroads 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Brown-Forman and Pernod Ricard in Merger Talks to Create World's Largest Spirits Giant 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CAMBRIDGE, Mass., Jan. 04, 2017 -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a question and answer session at the 35th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2017, at 11:30 a.m. PT in San Francisco, CA.
A live webcast of the presentation and question and answer session will be available on the Investors & Media section of the Editas website at www.editasmedicine.com. An archived replay will be available for approximately 30 days following the presentation.
About Editas Medicine
Editas Medicine is a leading genome editing company dedicated to treating patients with genetically-defined diseases by correcting their disease-causing genes. The company was founded by world leaders in genome editing, and its mission is to translate the promise of genome editing science into a broad class of transformative genomic medicines to benefit the greatest number of patients.
Media Contact Dan Budwick Pure Communications, Inc. (973) 271-6085 [email protected] Investor Contact Mark Mullikin Editas Medicine, Inc. (617) 401-9083 [email protected]
